Udelson JE, Goldsmith SR, Burkhoff D, Colorado P, et al. A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trial. Eur J Heart Fail 2025 Aug 11. doi: 10.1002/ejhf.3801.
PMID: 40788619